TY - JOUR
T1 - A Nationwide Survey of Pediatric-onset Japanese Encephalitis in Japan
AU - Nanishi, Etsuro
AU - Hoshina, Takayuki
AU - Sanefuji, Masafumi
AU - Kadoya, Ryo
AU - Kitazawa, Katsuhiko
AU - Arahata, Yukie
AU - Sato, Tetsuya
AU - Hirayama, Yoshimichi
AU - Hirai, Katsuki
AU - Yanai, Masaaki
AU - Nikaido, Kaori
AU - Maeda, Akihiko
AU - Torisu, Hiroyuki
AU - Okada, Kenji
AU - Sakai, Yasunari
AU - Ohga, Shouichi
N1 - Publisher Copyright:
© 2018 The Author(s) 2018.
PY - 2019/6
Y1 - 2019/6
N2 - Background: Japanese encephalitis (JE) is the leading cause of viral encephalitis with high mortality and morbidity in Asia. In Japan, however, the active recommendation of JE vaccine was retracted in 2005 because of the potential risk of acute disseminated encephalomyelitis. We aimed to determine the recent incidence of childhood-onset JE after the domestic change of vaccination policy in Japan, and to analyze the clinical features of affected children. Methods: A retrospective nationwide survey was conducted for pediatric patients with JE in Japan from 1995 to 2015. The national surveillance system was used to identify the pediatric patients with JE. Follow-up questionnaires were sent to analyze their clinical and neuroimaging profiles. Results: Among a total of 109 patients registered to the national surveillance, 10 (9%) were less than age 15 years. The annual incidence rate of childhood-onset JE was higher during 2005-15 than that during 1995-2004 (4.3 × 10-3 vs 1.1 × 10-3 per 100000, respectively; P =. 04). Endemic regions overlapped with prefectures that farmed pigs harboring antibodies against JE virus with high prevalence. Detailed clinical data were collected from 9 patients. None of them died, but 5 of 9 patients (56%) had neurological sequelae after recovery. One patient who was partially vaccinated with 2 doses of JE vaccine fully recovered from a coma. The age of 3 years or less was associated with unfavorable neurological prognosis. Conclusions: Our data provide evidence for the importance and prophylactic effect of the JE vaccine in young children in the endemic area.
AB - Background: Japanese encephalitis (JE) is the leading cause of viral encephalitis with high mortality and morbidity in Asia. In Japan, however, the active recommendation of JE vaccine was retracted in 2005 because of the potential risk of acute disseminated encephalomyelitis. We aimed to determine the recent incidence of childhood-onset JE after the domestic change of vaccination policy in Japan, and to analyze the clinical features of affected children. Methods: A retrospective nationwide survey was conducted for pediatric patients with JE in Japan from 1995 to 2015. The national surveillance system was used to identify the pediatric patients with JE. Follow-up questionnaires were sent to analyze their clinical and neuroimaging profiles. Results: Among a total of 109 patients registered to the national surveillance, 10 (9%) were less than age 15 years. The annual incidence rate of childhood-onset JE was higher during 2005-15 than that during 1995-2004 (4.3 × 10-3 vs 1.1 × 10-3 per 100000, respectively; P =. 04). Endemic regions overlapped with prefectures that farmed pigs harboring antibodies against JE virus with high prevalence. Detailed clinical data were collected from 9 patients. None of them died, but 5 of 9 patients (56%) had neurological sequelae after recovery. One patient who was partially vaccinated with 2 doses of JE vaccine fully recovered from a coma. The age of 3 years or less was associated with unfavorable neurological prognosis. Conclusions: Our data provide evidence for the importance and prophylactic effect of the JE vaccine in young children in the endemic area.
UR - http://www.scopus.com/inward/record.url?scp=85067287570&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067287570&partnerID=8YFLogxK
U2 - 10.1093/cid/ciy816
DO - 10.1093/cid/ciy816
M3 - Review article
C2 - 30252025
AN - SCOPUS:85067287570
SN - 1058-4838
VL - 68
SP - 2099
EP - 2104
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 12
M1 - ciy816
ER -